the room said yes. the rulebook has not moved yet.

On July 23 and 24, the Pharmacy Compounding Advisory Committee, or PCAC, considered whether seven peptide families should be eligible for the 503A Bulks List. That is the list of ingredients a state-licensed compounding pharmacy may use for an individual patient with a prescription, provided the pharmacy follows the rest of section 503A.

This was a vote about a possible compounding pathway. It was not a drug approval vote.

The scoreboard:

BPC-157
8 yes, 6 no, 1 abstention
KPV
8 yes, 6 no, 1 abstention
TB-500
8 yes, 6 no, 1 abstention
MOTS-c
7 yes, 5 no, 2 abstentions
epitalon
7 yes, 4 no, 1 abstention
semax
8 yes, 5 no, 1 abstention
emideltide / DSIP
6 yes, 7 no, 1 abstention
The split came down to two different ideas of what the committee was supposed to solve.

The yes bloc saw an access and harm-reduction question. People already buy these compounds online. Supporters argued that prescriptions, physician oversight, and licensed pharmacies could create a safer route than mystery vials from research-chemical sites. To them, the vote opened the door to regulated compounding. It did not certify that every claim was proven.

FDA staff and the no bloc saw an evidence question. Could a pharmacist reliably identify the substance? Could a compounder control impurities, aggregates, sterility, endotoxin, and stability? Was there enough human evidence to support a dose, route, use, and safety profile?

For most of the nominees, the answers were thin. “BPC-157” can mean a free base or acetate salt. “TB-500” is often used for both a short fragment and the much larger thymosin beta-4 protein. KPV and TB-500 had no human exposure data for the uses reviewed. MOTS-c leaned on cell and animal studies. Epitalon lacked clinical safety data for subcutaneous use. Semax had foreign clinical experience, especially from Russia, but FDA still found the evidence inadequate for the nominated neurological uses.

BPC-157 had the most familiar name, but FDA found only five small, short human studies with exploratory dosing and limited safety monitoring. The committee still passed it 8-6-1.

The voting pattern tells the story. For BPC-157, KPV, and TB-500, the eight yes votes came from the original bloc. All six temporary members seated for those topics voted no, and the NABP representative abstained. Three very different evidence files produced the same 8-6-1 result because the two groups were applying different thresholds.

Why did DSIP lose? Its insomnia studies were inconsistent, while the narcolepsy and opioid-withdrawal evidence came from tiny or uncontrolled reports. FDA found no effectiveness data for the proposed subcutaneous route. Intravenous studies also reported headache, nausea, vertigo, and progressive hypotension after a second injection. One access-friendly member switched to no because of the possible downstream harm.

In short: the six winners cleared the committee’s access argument. They did not clear FDA’s evidence standard. DSIP paired a weak file with a safety signal visible enough to break the coalition.

So what changes now? For patients, prescribers, compounders, and online vendors: nothing immediate. PCAC advises FDA. FDA can accept, narrow, or reject its recommendations. Adding a substance to the final 503A list normally requires a proposed rule, public comments, and a final rule. That can take months or years.

The votes are still meaningful. Six peptides now have the strongest federal access signal they have received, and current HHS leadership appears open to broader peptide compounding. But no peptide was approved, none joined the final list, and research-use-only sellers received no new permission to market products for humans.